Tokyo - Delayed Quote JPY

WIN-Partners Co., Ltd. (3183.T)

1,312.00
+22.00
+(1.71%)
At close: May 9 at 3:30:00 PM GMT+9
Loading Chart for 3183.T
  • Previous Close 1,290.00
  • Open 1,299.00
  • Bid --
  • Ask --
  • Day's Range 1,280.00 - 1,359.00
  • 52 Week Range 1,012.00 - 1,595.00
  • Volume 72,300
  • Avg. Volume 51,296
  • Market Cap (intraday) 37.51B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 18.94
  • EPS (TTM) 69.27
  • Earnings Date May 15, 2025
  • Forward Dividend & Yield 104.00 (7.93%)
  • Ex-Dividend Date Mar 28, 2025
  • 1y Target Est --

WIN-Partners Co., Ltd., through its subsidiaries, distributes medical devices to medical institutions primarily in Japan. The company offers percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters; pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters; and stent grafts, transcatheter heart valves, and mechanical heart valves. It also provides peripheral vascular stents, carotid artery stents, and embolic coils; and insulin pumps, as well as continuous glucose monitoring, and computed tomography equipment. WIN-Partners Co., Ltd. was founded in 1973 and is headquartered in Tokyo, Japan.

www.win-partners.co.jp

629

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 3183.T

View More

Performance Overview: 3183.T

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

3183.T
0.57%
Nikkei 225 (^N225)
5.99%

1-Year Return

3183.T
16.16%
Nikkei 225 (^N225)
1.50%

3-Year Return

3183.T
44.28%
Nikkei 225 (^N225)
42.49%

5-Year Return

3183.T
68.74%
Nikkei 225 (^N225)
85.85%

Compare To: 3183.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3183.T

View More

Valuation Measures

Annual
As of 5/9/2025
  • Market Cap

    37.51B

  • Enterprise Value

    21.66B

  • Trailing P/E

    18.93

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.46

  • Price/Book (mrq)

    1.65

  • Enterprise Value/Revenue

    0.27

  • Enterprise Value/EBITDA

    6.91

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.48%

  • Return on Assets (ttm)

    4.11%

  • Return on Equity (ttm)

    8.82%

  • Revenue (ttm)

    82.61B

  • Net Income Avi to Common (ttm)

    2.05B

  • Diluted EPS (ttm)

    69.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    15.54B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 3183.T

View More

Company Insights: 3183.T

Research Reports: 3183.T

View More

People Also Watch